Cox-2抑制剂Celecoxib放射治疗增敏作用的临床观察  

Clinical observation of the radiosensitizing effect of Celecoxib on nasopharyngeal carcinoma

作　　者：张福正[1] 邹勤舟[1] 赵涤非[1] 赵于天[1] 贺蓓娃[1] 周乐源[1] 楚建军[1] 

机构地区：[1]无锡市第四人民医院,江苏无锡214062

出　　处：《中国肿瘤临床与康复》2008年第1期48-50,共3页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的研究Cox-2抑制剂Celecoxib在头颈部肿瘤放射治疗中的增敏作用和副作用。方法自2005年6月至2007年5月,选择头颈肿瘤病例68例,随机分为常规组及Celecoxib组,常规组行单纯根治性放疗,Celecoxib组根治性放疗的同时用Celecoxib增敏。放疗方法:先制作面模固定,CT定位,做TPS计划,肿瘤临床病灶剂量为65～70Gy/6.5～7周,亚临床病灶剂量为45～50Gy。用药方法:Celecoxib每次200mg,每日2次口服,放疗开始和放疗结束。结果Celecoxib组和常规组原发灶有效率分别为91.7%和81.3%,而颈部淋巴结有效率分别为91.7%和80.0%,远处转移率分别为8.0%和17.4%。结论Celecoxib具有放射治疗增敏作用,与常规组相比差异有显著性,而且副作用少。但其长期疗效和副作用有待进一步观察和研究。Objective To study the radiosensitizing effect and the side effect of Celecoxib in radiotherapy of head and neck cancers, Methods Sixty-eight patients with head and neck cancers from June 2005 to May 2007 were randomized to two groups, routine group in which patients were given definitive radiotherapy only and Cox-2 group in which patients were given definitive radiotherapy combined with Celecoxib 200mg bid orally from the beginning to the end of the radiotherapy course. Results In the Cox2 group and routine group,the CR ＋ PR for local lesion was 91.7% and 81, 3% respectively, and for lymph node was 91,7% and 80, 0% respectively. The remote metastasis in the two groups was 8.0% and 17.4%. Conclusions Celecoxib could increase the radiosensitivity and there was significant difference between the two groups. It had little side effect. However, its long-term effect needs further study in the future.

关 键 词：头颈肿瘤/放射疗法 增敏 CELECOXIB 

分 类 号：R730.5[医药卫生—肿瘤]